ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kidswell Bio Corporation
  3. Financials
  4. Gross profit

Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross profit (Million JPY)YoY (%)
Mar 31, 20251,640+57.80%
Mar 31, 20241,039-31.87%
Mar 31, 20231,526+49.74%
Mar 31, 20221,019+16.18%
Mar 31, 2021877+106.55%
Mar 31, 2020425-30.32%
Mar 31, 2019609-4.39%
Mar 31, 2018637-7.92%
Mar 31, 2017692+4.83%
Mar 31, 2016660+279.29%
Mar 31, 2015174

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat